<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937390</url>
  </required_header>
  <id_info>
    <org_study_id>205.517</org_study_id>
    <nct_id>NCT01937390</nct_id>
  </id_info>
  <brief_title>Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Post-Marketing Observational Study of the Impact of Adherence to Treatment With Once-Daily Administered Long-Acting Bronchodilators (LABAs / LAMAs) on Patients Health Related Quality of Life in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to observe the effect of adherence to once-daily administered
      long-acting bronchodilators (long-acting ß2-agonists [LABAs] / long-acting muscarinic
      antagonists [LAMAs]) on patients health related quality of life (HR-QoL) and to assess the
      relation between symptoms improvement and adherence to Chronic Obstructive Pulmonary Disease
      (COPD) maintenance therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2011</start_date>
  <completion_date type="Actual">October 22, 2016</completion_date>
  <primary_completion_date type="Actual">October 22, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13</measure>
    <time_frame>Baseline and 13 Month</time_frame>
    <description>The Clinical COPD (Chronic Obstructive Pulmonary Disease) Questionnaire (CCQ) is a standardized, validated and reliable questionnaire (in local language) to assess the impact of treatment on health status in COPD patients. CCQ total score is calculated as the arithmetic average of 10 individual scores on a 7-point scale. CCQ total score varies from 0 (very good control) to 6 (extremely poor control). Mean change in CCQ total score from baseline at month 13 is presented along with its standard error. Change in CCQ total score is calculated for each subject as:
CCQ total score at month 13 - CCQ total score at baseline. Baseline is defined as the first assessment after enrolment (at Month 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CCQ Total Score at Month 13 (Visit 4)</measure>
    <time_frame>13 months</time_frame>
    <description>Mean and standard deviation of CCQ total score is presented at month 13.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of COPD Exacerbations Leading to Hospitalization, Per Patient</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of subjects hospitalized due to COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject is hospitalized due to COPD exacerbations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of COPD Exacerbations, Per Patient</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of subjects experienced COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject experienced COPD exacerbations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons of Non-adherence to Once-daily Long-acting Bronchodilators in COPD Patients</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of subjects corresponding to each reason of non-adherence to once-daily long-acting bronchodilators in COPD patients are presented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">645</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation</intervention_name>
    <description>Respimat® inhaler and cartridge Solution for inhalation</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacterol 300 µg</intervention_name>
    <description>inhalation powder</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule</intervention_name>
    <description>HandiHaler® device Inhalation powder, hard capsule</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacterol 150 µg</intervention_name>
    <description>inhalation powder</description>
    <arm_group_label>LAMA/LABA Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Caucasians
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female, above 40 years of age

          2. Patients clinically diagnosed of COPD with no history suggestive of asthma:

               1. by scores &gt;=5 in the COPD Population Screener,

               2. by a clinical diagnosis of COPD made by pulmonologists or internists,

               3. by a Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC6) ratio of
                  &lt;=0.70 and a FEV1 &lt;=80% of the predicted value as assessed by copd-6
                  (Vitalograph, UK);

          3. Maintenance treatment-naïve COPD patients who have been prescribed once daily
             long-acting bronchodilators (LABAs / LAMAs) for the first time at enrolment into the
             study

          4. Patients who are able to provide signed informed consent

          5. Patients who agree to be contacted for telephone/ SMS reminders via call center

        Exclusion criteria:

          1. Patients with contraindications to the prescribed medication

          2. Patients with any disorder that would prevent the patient from being able to complete
             questionnaires either verbally or by self-completion

          3. Pregnant or lactating women or women of childbearing potential not using an acceptable
             method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTMS MIGRATION CENTER representing all obvious CTMS Dummy Sites</name>
      <address>
        <city>Ingelheim am Rhein</city>
        <zip>55216</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Lebanon</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Synopsis Link</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <results_first_submitted>October 20, 2017</results_first_submitted>
  <results_first_submitted_qc>October 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2018</results_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 645 subjects were screened in this study, out of which 585 satisfied the selection criteria and were finally entered in to the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LAMA/LABA Patients</title>
          <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="585"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fail to return</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who meet all of the inclusion criteria and none of the exclusion criteria (including signing the informed consent) constituted the study population.</population>
      <group_list>
        <group group_id="B1">
          <title>LAMA/LABA Patients</title>
          <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="585"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13</title>
        <description>The Clinical COPD (Chronic Obstructive Pulmonary Disease) Questionnaire (CCQ) is a standardized, validated and reliable questionnaire (in local language) to assess the impact of treatment on health status in COPD patients. CCQ total score is calculated as the arithmetic average of 10 individual scores on a 7-point scale. CCQ total score varies from 0 (very good control) to 6 (extremely poor control). Mean change in CCQ total score from baseline at month 13 is presented along with its standard error. Change in CCQ total score is calculated for each subject as:
CCQ total score at month 13 - CCQ total score at baseline. Baseline is defined as the first assessment after enrolment (at Month 1).</description>
        <time_frame>Baseline and 13 Month</time_frame>
        <population>Intent-to-treat (ITT): This population set included all subjects who signed informed consent form (ICF), satisfied all inclusion and exclusion criteria and have taken at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LAMA/LABA Patients</title>
            <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13</title>
          <description>The Clinical COPD (Chronic Obstructive Pulmonary Disease) Questionnaire (CCQ) is a standardized, validated and reliable questionnaire (in local language) to assess the impact of treatment on health status in COPD patients. CCQ total score is calculated as the arithmetic average of 10 individual scores on a 7-point scale. CCQ total score varies from 0 (very good control) to 6 (extremely poor control). Mean change in CCQ total score from baseline at month 13 is presented along with its standard error. Change in CCQ total score is calculated for each subject as:
CCQ total score at month 13 - CCQ total score at baseline. Baseline is defined as the first assessment after enrolment (at Month 1).</description>
          <population>Intent-to-treat (ITT): This population set included all subjects who signed informed consent form (ICF), satisfied all inclusion and exclusion criteria and have taken at least one dose of study drug.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CCQ Total Score at Month 13 (Visit 4)</title>
        <description>Mean and standard deviation of CCQ total score is presented at month 13.</description>
        <time_frame>13 months</time_frame>
        <population>ITT (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>LAMA/LABA Patients</title>
            <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CCQ Total Score at Month 13 (Visit 4)</title>
          <description>Mean and standard deviation of CCQ total score is presented at month 13.</description>
          <population>ITT (observed cases)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of COPD Exacerbations Leading to Hospitalization, Per Patient</title>
        <description>Percentage of subjects hospitalized due to COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject is hospitalized due to COPD exacerbations.</description>
        <time_frame>13 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAMA/LABA Patients</title>
            <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Leading to Hospitalization, Per Patient</title>
          <description>Percentage of subjects hospitalized due to COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject is hospitalized due to COPD exacerbations.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of COPD Exacerbations, Per Patient</title>
        <description>Percentage of subjects experienced COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject experienced COPD exacerbations.</description>
        <time_frame>13 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAMA/LABA Patients</title>
            <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations, Per Patient</title>
          <description>Percentage of subjects experienced COPD exacerbations exactly &quot;n&quot; number of times during the study period is presented. Here, &quot;n&quot; represents the number of times each subject experienced COPD exacerbations.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons of Non-adherence to Once-daily Long-acting Bronchodilators in COPD Patients</title>
        <description>Percentage of subjects corresponding to each reason of non-adherence to once-daily long-acting bronchodilators in COPD patients are presented.</description>
        <time_frame>13 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAMA/LABA Patients</title>
            <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons of Non-adherence to Once-daily Long-acting Bronchodilators in COPD Patients</title>
          <description>Percentage of subjects corresponding to each reason of non-adherence to once-daily long-acting bronchodilators in COPD patients are presented.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Felt good and decided not to take it</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Felt good and forgot to take it</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not experience any significant improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ran out of medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to tolerate side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrolment in the study till end of study; up to 13 months.</time_frame>
      <desc>ITT Population</desc>
      <group_list>
        <group group_id="E1">
          <title>LAMA/LABA Patients</title>
          <description>Patients taking once daily oral inhalation of Long-acting bronchodilators (long-acting β2-agonists [LABAs]/ long-acting muscarinic antagonists [LAMAs]) during the study period of 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version:19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

